Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Lixumistat by Immunomet Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Lixumistat is under clinical development by Immunomet Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData,...